Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection

Open access

Abstract

The SARS-CoV-2 Omicron variant evades most currently approved neutralizing antibodies (nAbs) and caused drastic decrease of plasma neutralizing activity elicited by vaccination or prior infection, urging the need for the development of pan-variant antivirals. Breakthrough infection induces a hybrid immunological response with potentially broad, potent and durable protection against variants, therefore, convalescent plasma from breakthrough infection may provide a broadened repertoire for identifying elite nAbs. We performed single-cell RNA sequencing (scRNA-seq) and BCR sequencing (scBCR-seq) of B cells from BA.1 breakthrough-infected patients who received 2 or 3 previous doses of inactivated vaccine. Elite nAbs, mainly derived from the IGHV2–5 and IGHV3-66/53 germlines, showed potent neutralizing activity across Wuhan-Hu-1, Delta, Omicron sublineages BA.1 and BA.2 at picomolar NT 50 values. Cryo-EM analysis revealed diverse modes of spike recognition and guides the design of cocktail therapy. A single injection of paired antibodies cocktail provided potent protection in the K18-hACE2 transgenic female mouse model of SARS-CoV-2 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-39267-x

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of high-confidence clonotypes by single-cell transcriptomic and BCR profiling. a Schematic diagram of the experimental design. Single-cell RNA-seq and single-cell BCR-seq were conducted for CD19+ RBD+ B cells derived from 38 Omicron patients, followed by clonotype detection and experimental verification. b UMAP display of 277,630 B cells. Orange and blue correspond to memory B cells and naïve B cells, which are characterized by high expression of CD27/GPR183 and TCL1A/IL4R/IGHD, respectively. c Filter criteria for the selection of high-confidence clonotypes. d Distribution of frequency, memory B-cell number, and SHM for 286 high-confidence candidates. SHM somatic hypermutation rate. e VDJ gene rearrangements for heavy chains of the 286 high-confidence candidates. f VDJ gene rearrangements for light chains of the 286 high-confidence candidates.
Fig. 1 Identification of high-confidence clonotypes by single-cell transcriptomic and BCR profiling. a Schematic diagram of the experimental design. Single-cell RNA-seq and single-cell BCR-seq were conducted for CD19+ RBD+ B cells derived from 38 Omicron patients, followed by clonotype detection and experimental verification. b UMAP display of 277,630 B cells. Orange and blue correspond to memory B cells and naïve B cells, which are characterized by high expression of CD27/GPR183 and TCL1A/IL4R/IGHD, respectively. c Filter criteria for the selection of high-confidence clonotypes. d Distribution of frequency, memory B-cell number, and SHM for 286 high-confidence candidates. SHM somatic hypermutation rate. e VDJ gene rearrangements for heavy chains of the 286 high-confidence candidates. f VDJ gene rearrangements for light chains of the 286 high-confidence candidates.CC BY · PubMed Central
Fig. 2 Discovery and characterization of isolated neutralizing antibodies. a Evaluation of the binding of 286 antibodies to SARS-CoV-2 variants, measured by ELISA. The OD450 values of each mAb against WT S protein, Omicron BA.1.1 S protein, and Omicron BA.1.1 RBD are shown. The balls in purple indicate 119 mAbs selected for further study (left). Evaluation of the blocking abilities of 119 antibodies against SARS-CoV-2 variants, measured by ELISA. The IC50 values of each mAb against WT RBD, Delta RBD, Omicron BA.1.1 RBD are shown. The red balls refer to 44 potent neutralizing mAbs for further experiments. The ball size represents the number of antibodies. Sixty-four mAbs had no blocking ability against any variants, represented by the large gray ball (the IC50 values shown as NA) (middle). Evaluation of the neutralizing activity of 44 antibodies against SARS-CoV-2 variants. The NT50 values of each mAb against the WT strain, Delta strain, and Omicron BA.2 are shown. The balls in orange indicate 19 mAbs selected for further study (right). b Neutralization curves for the 19 selected antibodies against WT virus or VOCs. (n = 3 technical replicates). Data are presented as mean values ± SD. All experiments were performed in duplicate. c Neutralization potency of the 19 selected antibodies against different SARS-CoV-2 strains.
Fig. 2 Discovery and characterization of isolated neutralizing antibodies. a Evaluation of the binding of 286 antibodies to SARS-CoV-2 variants, measured by ELISA. The OD450 values of each mAb against WT S protein, Omicron BA.1.1 S protein, and Omicron BA.1.1 RBD are shown. The balls in purple indicate 119 mAbs selected for further study (left). Evaluation of the blocking abilities of 119 antibodies against SARS-CoV-2 variants, measured by ELISA. The IC50 values of each mAb against WT RBD, Delta RBD, Omicron BA.1.1 RBD are shown. The red balls refer to 44 potent neutralizing mAbs for further experiments. The ball size represents the number of antibodies. Sixty-four mAbs had no blocking ability against any variants, represented by the large gray ball (the IC50 values shown as NA) (middle). Evaluation of the neutralizing activity of 44 antibodies against SARS-CoV-2 variants. The NT50 values of each mAb against the WT strain, Delta strain, and Omicron BA.2 are shown. The balls in orange indicate 19 mAbs selected for further study (right). b Neutralization curves for the 19 selected antibodies against WT virus or VOCs. (n = 3 technical replicates). Data are presented as mean values ± SD. All experiments were performed in duplicate. c Neutralization potency of the 19 selected antibodies against different SARS-CoV-2 strains.CC BY · PubMed Central
Fig. 3 Evaluation of elite antibodies against Omicron BA.2.12.1 and BA.4 & 5. a Details of the 19 selected antibodies. The seven groups of antibodies are shown in different colors, and the asterisks indicate representative antibodies. b Binding kinetics of the seven candidate antibodies (TH003, TH027, TH048, TH236, TH257, TH272, and TH281) with the S protein of the Omicron BA.1 and BA.4/5 variants were measured by the SPR assay. c Omicron BA.2.12.1 or BA.4 & 5 SARS-CoV-2-S pseudotyped virus neutralization. (n = 3 technical replicates). Data are presented as mean values ± SD.
Fig. 3 Evaluation of elite antibodies against Omicron BA.2.12.1 and BA.4 & 5. a Details of the 19 selected antibodies. The seven groups of antibodies are shown in different colors, and the asterisks indicate representative antibodies. b Binding kinetics of the seven candidate antibodies (TH003, TH027, TH048, TH236, TH257, TH272, and TH281) with the S protein of the Omicron BA.1 and BA.4/5 variants were measured by the SPR assay. c Omicron BA.2.12.1 or BA.4 & 5 SARS-CoV-2-S pseudotyped virus neutralization. (n = 3 technical replicates). Data are presented as mean values ± SD.CC BY · PubMed Central
Fig. 4 Cryo-EM structures of the Omicron BA.4/5 spike in complex with elite nAbs. a The structures of the BA.4/5 S trimer in complex with TH003, TH027, TH236, TH272, TH132, and TH281 are displayed in cartoon representation. TH003, TH027, TH236, TH272, TH132, and TH281 are colored pink, purple blue, purple, green, yellow, and orange, respectively, and the S trimer is colored gray. Side view (top), top view (bottom). b The epitopes of antibodies are displayed in surface representation. The colors are the same as in a, and the hACE2 interface is circled in red.
Fig. 4 Cryo-EM structures of the Omicron BA.4/5 spike in complex with elite nAbs. a The structures of the BA.4/5 S trimer in complex with TH003, TH027, TH236, TH272, TH132, and TH281 are displayed in cartoon representation. TH003, TH027, TH236, TH272, TH132, and TH281 are colored pink, purple blue, purple, green, yellow, and orange, respectively, and the S trimer is colored gray. Side view (top), top view (bottom). b The epitopes of antibodies are displayed in surface representation. The colors are the same as in a, and the hACE2 interface is circled in red.CC BY · PubMed Central
Fig. 5 Rational pairings of noncompeting antibodies show promising therapeutic potential for antibody therapy against emerging VOC. a The overall structure of TH027-BA.4/5 RBD. The TH027 heavy chain (colored deep blue) and light chain (colored yellow) are displayed in cartoon representation. The BA.4/5 RBD is colored gray and displayed in surface representation (left). The epitope of TH027 is shown in surface representation. The only residue V445, which contacts both the heavy chain and light chain, is colored pink (right). b The interface of TH027-BA.4/5 RBD. Hydrogen bond interactions are shown as yellow dashed lines. Salt bridge interactions are shown as green dashed lines. The residues are shown in stick representation with the same colors as in a. c The overall structure of TH132-BA.4/5 RBD. The TH132 heavy chain (colored orange) and light chain (colored green) are displayed in cartoon representation. BA.4/5 RBD is colored in gray and displayed in surface representation (left). The epitope of TH132 is shown in surface representation. The only residue that contacts both the heavy chain and light chain, N417, is colored yellow (right). d The interface of TH132-BA.4/5 RBD. Hydrogen bond interactions are shown as yellow dashed lines. The residues are shown in stick representation with identical colors to c. e The structure of the BA.4/5 S trimer in complex with the TH027 + TH132 cocktail, and neutralization potency of the TH027 + TH132 cocktail against different sublineages of Omicron strains. S trimer is displayed in gray surface representation. RBD is colored pink. TH027 + TH132 are displayed in cartoon representation. TH027 is colored in deep blue. TH132 is colored yellow. Side view (left). Top view (right). f The structure of the BA.4/5 S trimer in complex with the TH272 + TH281 cocktail, and neutralization potency of the TH272 + TH281 cocktail against different sublineages of Omicron strains. S trimer is displayed in gray surface representation. RBD is colored pink. TH272 + TH281 are displayed in cartoon representation. TH272 is colored green. TH281 is colored orange. Side view (left). Top view (right).
Fig. 5 Rational pairings of noncompeting antibodies show promising therapeutic potential for antibody therapy against emerging VOC. a The overall structure of TH027-BA.4/5 RBD. The TH027 heavy chain (colored deep blue) and light chain (colored yellow) are displayed in cartoon representation. The BA.4/5 RBD is colored gray and displayed in surface representation (left). The epitope of TH027 is shown in surface representation. The only residue V445, which contacts both the heavy chain and light chain, is colored pink (right). b The interface of TH027-BA.4/5 RBD. Hydrogen bond interactions are shown as yellow dashed lines. Salt bridge interactions are shown as green dashed lines. The residues are shown in stick representation with the same colors as in a. c The overall structure of TH132-BA.4/5 RBD. The TH132 heavy chain (colored orange) and light chain (colored green) are displayed in cartoon representation. BA.4/5 RBD is colored in gray and displayed in surface representation (left). The epitope of TH132 is shown in surface representation. The only residue that contacts both the heavy chain and light chain, N417, is colored yellow (right). d The interface of TH132-BA.4/5 RBD. Hydrogen bond interactions are shown as yellow dashed lines. The residues are shown in stick representation with identical colors to c. e The structure of the BA.4/5 S trimer in complex with the TH027 + TH132 cocktail, and neutralization potency of the TH027 + TH132 cocktail against different sublineages of Omicron strains. S trimer is displayed in gray surface representation. RBD is colored pink. TH027 + TH132 are displayed in cartoon representation. TH027 is colored in deep blue. TH132 is colored yellow. Side view (left). Top view (right). f The structure of the BA.4/5 S trimer in complex with the TH272 + TH281 cocktail, and neutralization potency of the TH272 + TH281 cocktail against different sublineages of Omicron strains. S trimer is displayed in gray surface representation. RBD is colored pink. TH272 + TH281 are displayed in cartoon representation. TH272 is colored green. TH281 is colored orange. Side view (left). Top view (right).CC BY · PubMed Central
Fig. 6 Evaluation of in vivo efficacy of prophylactic and therapeutic TH027 + TH132 cocktail. a Experimental design for TH027 + TH132 cocktail efficacy evaluation in K18-hACE2 transgenic mice. b Mice were intraperitoneally injected with a single injection of 5 or 20 mg/kg of TH027, TH132, or TH027 + TH132 cocktail 2 h before or after an intranasal challenge of 1 × 104 TCID50 BA.5 virus. Body weight of mice were monitored daily until 6 days post-infection (d.p.i.). (PBS and TH027 + TH132/20 mpk on before 2 d.p.i.: n = 6 mice, other groups: n = 5 mice. PBS and TH027 + TH132/20 mpk on after 2 d.p.i.: n = 3 mice, other groups: n = 2 mice). c Viral RNA levels in the lung tissue were measured by qRT–PCR assay at 2 d.p.i. (n = 3 mice). d Viral titers in the lung tissue were measured by fluorescence focus assay at 2 d.p.i. (n = 3 mice). e Histopathological and immunofluorescence analyses of TH027, TH132, or TH027 + TH132 cocktail treated or untreated mice infected with Omicron BA.5. Representative images of lung sections stained by HE in antibodies prophylactic and therapeutic groups at 6 d.p.i. The images of bronchioles, blood vessels, and alveoli of the lungs are indicated by black dotted squares with numbers 1, 2, and 3, respectively. The images on the right (bars = 50 μm) are enlarged regions in the dashed boxes of the left images (bars = 500 μm). Red, blue, green, yellow, black, and purple arrows indicate necrotic epithelial cells in the alveoli, dead cell debris in the bronchioles, severe bleeding in the alveoli, a large amount of protein mucus in the lungs, mononuclear cell infiltrations in the blood vessels and inflammatory infiltrations in the lungs, respectively. Representative images of the N protein expression in the lungs at 6 d.p.i. (bars = 50 μm). Three mice were sampled in each group and 5 sections from each animal were used for histology analysis. All data are presented as mean values ± SD. Statistical differences were determined by two-way ANOVA in c, d. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 6 Evaluation of in vivo efficacy of prophylactic and therapeutic TH027 + TH132 cocktail. a Experimental design for TH027 + TH132 cocktail efficacy evaluation in K18-hACE2 transgenic mice. b Mice were intraperitoneally injected with a single injection of 5 or 20 mg/kg of TH027, TH132, or TH027 + TH132 cocktail 2 h before or after an intranasal challenge of 1 × 104 TCID50 BA.5 virus. Body weight of mice were monitored daily until 6 days post-infection (d.p.i.). (PBS and TH027 + TH132/20 mpk on before 2 d.p.i.: n = 6 mice, other groups: n = 5 mice. PBS and TH027 + TH132/20 mpk on after 2 d.p.i.: n = 3 mice, other groups: n = 2 mice). c Viral RNA levels in the lung tissue were measured by qRT–PCR assay at 2 d.p.i. (n = 3 mice). d Viral titers in the lung tissue were measured by fluorescence focus assay at 2 d.p.i. (n = 3 mice). e Histopathological and immunofluorescence analyses of TH027, TH132, or TH027 + TH132 cocktail treated or untreated mice infected with Omicron BA.5. Representative images of lung sections stained by HE in antibodies prophylactic and therapeutic groups at 6 d.p.i. The images of bronchioles, blood vessels, and alveoli of the lungs are indicated by black dotted squares with numbers 1, 2, and 3, respectively. The images on the right (bars = 50 μm) are enlarged regions in the dashed boxes of the left images (bars = 500 μm). Red, blue, green, yellow, black, and purple arrows indicate necrotic epithelial cells in the alveoli, dead cell debris in the bronchioles, severe bleeding in the alveoli, a large amount of protein mucus in the lungs, mononuclear cell infiltrations in the blood vessels and inflammatory infiltrations in the lungs, respectively. Representative images of the N protein expression in the lungs at 6 d.p.i. (bars = 50 μm). Three mice were sampled in each group and 5 sections from each animal were used for histology analysis. All data are presented as mean values ± SD. Statistical differences were determined by two-way ANOVA in c, d. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022). · doi:10.1038/s41586-021-04387-1 · Paper page

Cited by

See all 28

Metadata

Authors
Guo, Y., Zhang, G., Yang, Q., Xie, X., Lu, Y., Cheng, X., Wang, H., Liang, J., Tang, J., Gao, Y., Shang, H., Dai, J., Shi, Y., Zhou, J., Zhou, J., Guo, H., Yang, H., Qi, J., Liu, L., Ma, S., Zhang, B., Huo, Q., Xie, Y., Wu, J., Dong, F., Zhang, S., Lou, Z., Gao, Y., Song, Z., Wang, W., Sun, Z., Yang, X., Xiong, D., Liu, F., Chen, X., Zhu, P., Wang, X., Cheng, T., & Rao, Z.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Nankai University (CN)
  • Guangzhou Laboratory (CN)
  • ShanghaiTech University (CN)
  • Tianjin haihe hospital (CN)
Corresponding author
  • Guo, Yu
  • Yang, Qi
  • Yang, Xiaoming
  • Xiong, Dongsheng
  • Liu, Fengjiang
  • Chen, Xinwen
  • Zhu, Ping
  • Wang, Ximo
  • Cheng, Tao
  • Rao, Zihe
Venue
Nature Communications
Published
2023-06-15
Volume
14
Issue
1
Pages
3537-3537
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4380681008
Cited by
28
References
54
Citations by year
2026: 9 · 2025: 9 · 2024: 9 · 2023: 1
FWCI
5.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81890990, 81730006, 32271256)
  • ShanghaiTech University
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
Omicron variant, neutralizing antibodies, breakthrough infection, convalescent plasma, BA.1, BA.2, B cell receptor repertoire, vaccine escape, single-cell RNA sequencing
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Breakthrough Infections, Animals, Antibodies, Viral, Female, Mice, Transgenic, Mice, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection. https://app.cochat.ai/papers/10.1038/s41467-023-39267-x
The paper
Guo, Y., Zhang, G., Yang, Q., Xie, X., Lu, Y., Cheng, X., Wang, H., Liang, J., Tang, J., Gao, Y., Shang, H., Dai, J., Shi, Y., Zhou, J., Zhou, J., Guo, H., Yang, H., Qi, J., Liu, L., . . . Rao, Z. (2023). Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection. Nature Communications. https://doi.org/10.1038/s41467-023-39267-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.